Saniona AB (publ) (SANION.ST)
SEK 8.05
(3.34%)
SEK 8.05
(3.34%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 40.44 Million SEK | 234.0% |
| 2022 | -30.18 Million SEK | 88.26% |
| 2021 | -257.08 Million SEK | 51.16% |
| 2020 | -526.35 Million SEK | -1255.61% |
| 2019 | -38.82 Million SEK | 20.24% |
| 2018 | -48.67 Million SEK | -118.16% |
| 2017 | -22.31 Million SEK | 58.11% |
| 2016 | -53.26 Million SEK | -13.31% |
| 2015 | -47 Million SEK | -385.13% |
| 2014 | -9.68 Million SEK | 14.32% |
| 2013 | -11.3 Million SEK | -58.12% |
| 2012 | -7.15 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -4.68 Million SEK | -111.59% |
| 2024 Q2 | 15.95 Million SEK | 440.32% |
| 2023 Q3 | 18.03 Million SEK | 525.35% |
| 2023 FY | 40.44 Million SEK | 234.0% |
| 2023 Q1 | -6.67 Million SEK | 77.88% |
| 2023 Q4 | 40.44 Million SEK | 124.27% |
| 2023 Q2 | 2.88 Million SEK | 143.2% |
| 2022 Q1 | -180.65 Million SEK | 29.73% |
| 2022 Q3 | -35.58 Million SEK | 52.79% |
| 2022 Q4 | -30.18 Million SEK | 15.17% |
| 2022 FY | -30.18 Million SEK | 88.26% |
| 2022 Q2 | -75.37 Million SEK | 58.27% |
| 2021 Q4 | -257.08 Million SEK | 20.84% |
| 2021 FY | -257.08 Million SEK | 51.16% |
| 2021 Q3 | -324.78 Million SEK | 18.92% |
| 2021 Q2 | -400.54 Million SEK | 15.71% |
| 2021 Q1 | -475.18 Million SEK | 9.72% |
| 2020 Q4 | -526.35 Million SEK | 11.82% |
| 2020 Q1 | -11.03 Million SEK | 71.58% |
| 2020 FY | -526.35 Million SEK | -1255.61% |
| 2020 Q2 | -33.55 Million SEK | -204.1% |
| 2020 Q3 | -596.91 Million SEK | -1679.14% |
| 2019 Q4 | -38.82 Million SEK | 30.59% |
| 2019 FY | -38.82 Million SEK | 20.24% |
| 2019 Q1 | -35.98 Million SEK | 26.09% |
| 2019 Q2 | -16.76 Million SEK | 53.41% |
| 2019 Q3 | -55.94 Million SEK | -233.71% |
| 2018 Q3 | -36.29 Million SEK | -479.37% |
| 2018 FY | -48.67 Million SEK | -118.16% |
| 2018 Q4 | -48.67 Million SEK | -34.13% |
| 2018 Q1 | -15.44 Million SEK | 30.76% |
| 2018 Q2 | -6.26 Million SEK | 59.45% |
| 2017 Q1 | -42.24 Million SEK | 20.68% |
| 2017 FY | -22.31 Million SEK | 58.11% |
| 2017 Q3 | -40.86 Million SEK | 36.88% |
| 2017 Q4 | -22.31 Million SEK | 45.4% |
| 2017 Q2 | -64.75 Million SEK | -53.26% |
| 2016 Q2 | -34 Million SEK | 30.43% |
| 2016 Q1 | -48.87 Million SEK | -3.98% |
| 2016 FY | -53.26 Million SEK | -13.31% |
| 2016 Q4 | -53.26 Million SEK | 16.38% |
| 2016 Q3 | -63.69 Million SEK | -87.33% |
| 2015 Q4 | -47 Million SEK | -277.36% |
| 2015 FY | -47 Million SEK | -385.13% |
| 2015 Q1 | -29.32 Million SEK | -202.61% |
| 2015 Q2 | -22.97 Million SEK | 21.65% |
| 2015 Q3 | -12.45 Million SEK | 45.78% |
| 2014 FY | -9.68 Million SEK | 14.32% |
| 2014 Q2 | -18.86 Million SEK | 0.0% |
| 2014 Q3 | -14.17 Million SEK | 24.89% |
| 2014 Q4 | -9.68 Million SEK | 31.62% |
| 2013 FY | -11.3 Million SEK | -58.12% |
| 2012 FY | -7.15 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -50.02 Million SEK | 180.86% |
| Ziccum AB (publ) | -2.13 Million SEK | 1992.7% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | 312.209% |
| BioArctic AB (publ) | -606.58 Million SEK | 106.668% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | 181.001% |
| Mendus AB (publ) | -96.29 Million SEK | 142.004% |
| Genovis AB (publ.) | -43.94 Million SEK | 192.048% |
| Intervacc AB (publ) | -88.16 Million SEK | 145.879% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | -97.206% |
| Active Biotech AB (publ) | -33.2 Million SEK | 221.828% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 24.005% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | 202.704% |
| Aptahem AB (publ) | 2.9 Million SEK | -1290.58% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 112.124% |
| Kancera AB (publ) | -45.69 Million SEK | 188.521% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 112.292% |
| Fluicell AB (publ) | -2.76 Million SEK | 1563.88% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | 226.686% |
| Biovica International AB (publ) | -58.73 Million SEK | 168.861% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | 189.451% |
| AcouSort AB (publ) | -23.98 Million SEK | 268.628% |
| Xintela AB (publ) | -7.8 Million SEK | 617.954% |
| Abliva AB (publ) | -57.24 Million SEK | 170.662% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 120.774% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 149.204% |
| OncoZenge AB (publ) | -12.62 Million SEK | 420.322% |
| Amniotics AB (publ) | -5.63 Million SEK | 818.164% |
| 2cureX AB (publ) | -13.4 Million SEK | 401.776% |
| CombiGene AB (publ) | -101.44 Million SEK | 139.873% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | 1971.68% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | -649.019% |
| Camurus AB (publ) | -1.16 Billion SEK | 103.471% |
| Corline Biomedical AB | -17.01 Million SEK | 337.756% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 148.299% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 129.278% |
| I-Tech AB | -83.26 Million SEK | 148.578% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 69.974% |
| Cyxone AB (publ) | -16.67 Million SEK | 342.633% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | 172.374% |
| Biosergen AB | -1.88 Million SEK | 2248.008% |
| Cantargia AB (publ) | -139.74 Million SEK | 128.943% |
| NextCell Pharma AB | -46.79 Million SEK | 186.443% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 131.234% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | 237.655% |
| Nanologica AB (publ) | -9.38 Million SEK | 530.837% |
| SynAct Pharma AB | -61.75 Million SEK | 165.493% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | 288.872% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | 405.741% |
| LIDDS AB (publ) | -13.51 Million SEK | 399.341% |
| Lipum AB (publ) | -8.46 Million SEK | 577.815% |
| BioInvent International AB (publ) | -236.3 Million SEK | 117.117% |
| Alzinova AB (publ) | -21.22 Million SEK | 290.554% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 160.441% |
| Pila Pharma AB (publ) | -5.18 Million SEK | 880.691% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 148.3% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | 4482.124% |
| Simris Alg AB (publ) | 85.07 Million SEK | 52.457% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 149.274% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 75.646% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | 294.522% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | 1460.935% |